OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China
Danling Gu, Jianyong Li, Yi Miao
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 18, pp. 1979-1986
Closed Access | Times Cited: 9
Danling Gu, Jianyong Li, Yi Miao
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 18, pp. 1979-1986
Closed Access | Times Cited: 9
Showing 9 citing articles:
Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2400-2400
Open Access | Times Cited: 34
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2400-2400
Open Access | Times Cited: 34
Challenges associated with the use of Bruton's tyrosine kinase inhibitors: A life‑saving therapy for chronic lymphocytic leukemia (Review)
Romeo-Gabriel Mihăilă
World Academy of Sciences Journal (2024) Vol. 6, Iss. 3
Open Access | Times Cited: 1
Romeo-Gabriel Mihăilă
World Academy of Sciences Journal (2024) Vol. 6, Iss. 3
Open Access | Times Cited: 1
The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies
Paweł Robak, Magdalena Witkowska, Anna Wolska, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 10, pp. 1065-1076
Closed Access | Times Cited: 4
Paweł Robak, Magdalena Witkowska, Anna Wolska, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 10, pp. 1065-1076
Closed Access | Times Cited: 4
A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications
Qi Zhang, Changming Wen, Zhao Li-jie, et al.
Molecules (2023) Vol. 28, Iss. 24, pp. 8037-8037
Open Access | Times Cited: 3
Qi Zhang, Changming Wen, Zhao Li-jie, et al.
Molecules (2023) Vol. 28, Iss. 24, pp. 8037-8037
Open Access | Times Cited: 3
Determination of Orelabrutinib in Human Plasma Using LC-MS/MS
Yang Zhao, Yu‐Jiao Guo, Xiang‐Long Chen, et al.
Therapeutic Drug Monitoring (2023)
Closed Access | Times Cited: 1
Yang Zhao, Yu‐Jiao Guo, Xiang‐Long Chen, et al.
Therapeutic Drug Monitoring (2023)
Closed Access | Times Cited: 1
Synthesis and application of small molecules approved for the treatment of lymphoma
Yuanyuan Guo, Jingyi Zhang, Jinfeng Sun, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115835-115835
Closed Access | Times Cited: 1
Yuanyuan Guo, Jingyi Zhang, Jinfeng Sun, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115835-115835
Closed Access | Times Cited: 1
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Huayuan Zhu, Yi Miao, Yeqin Sha, et al.
Research Square (Research Square) (2023)
Open Access
Huayuan Zhu, Yi Miao, Yeqin Sha, et al.
Research Square (Research Square) (2023)
Open Access
Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases
Pei Lin, Dandan Zhang, Jun Lin
Current Topics in Medicinal Chemistry (2023) Vol. 23, Iss. 28, pp. 2609-2620
Closed Access
Pei Lin, Dandan Zhang, Jun Lin
Current Topics in Medicinal Chemistry (2023) Vol. 23, Iss. 28, pp. 2609-2620
Closed Access
Cost–effectiveness of BTK inhibitors vs bendamustine and rituximab in chronic lymphocytic leukemia patients
Jing Nie, Huina Wu, Qian Wu, et al.
Future Oncology (2023) Vol. 19, Iss. 38, pp. 2525-2536
Closed Access
Jing Nie, Huina Wu, Qian Wu, et al.
Future Oncology (2023) Vol. 19, Iss. 38, pp. 2525-2536
Closed Access
